A share price of Vir Biotechnology Inc [VIR] is currently trading at $8.15, up 2.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The VIR shares have gain 14.47% over the last week, with a monthly amount glided 8.81%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on January 29, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $9 from $23. Previously, BofA Securities downgraded its rating to Neutral on September 08, 2023, and dropped its price target to $14. On March 06, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $34 on the stock. Goldman upgraded its rating to a Buy and increased its price target to $53 on February 21, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $30 on January 27, 2023. SVB Leerink started tracking with a Outperform rating for this stock on September 14, 2022, and assigned it a price target of $40. In a note dated September 09, 2022, Morgan Stanley initiated an Underweight rating and provided a target price of $15 on this stock.
Vir Biotechnology Inc experienced fluctuations in its stock price throughout the past year between $6.56 and $13.09. Currently, Wall Street analysts expect the stock to reach $26.6 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $8.15 at the most recent close of the market. An investor can expect a potential return of 226.38% based on the average VIR price forecast.
Analyzing the VIR fundamentals
Trailing Twelve Months sales for Vir Biotechnology Inc [NASDAQ:VIR] were 78.62M which represents -9.81% decline. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -6.58%, Pretax Profit Margin comes in at -6.86%, and Net Profit Margin reading is -6.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.37 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.92 points at the first support level, and at 7.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.37, and for the 2nd resistance point, it is at 8.60.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vir Biotechnology Inc [NASDAQ:VIR] is 8.94. On the other hand, the Quick Ratio is 8.94, and the Cash Ratio is 1.44. Considering the valuation of this stock, the price to sales ratio is 14.46, the price to book ratio is 0.90.
Transactions by insiders
Recent insider trading involved VANINA ALEXANDRA HUARD DE VERN, Officer, that happened on Dec 02 ’24 when 76.0 shares were purchased. EVP and General Counsel, de Verneuil Vanina completed a deal on Nov 06 ’24 to sell 4397.0 shares. Meanwhile, Officer VANINA DE VERNEUIL bought 4397.0 shares on Nov 06 ’24.
